Drug repurposing: re-inventing therapies for cancer without re-entering the development pipeline—a review

Siddiqui, Shafina; Deshmukh, Ankita Jaywant; Mudaliar, Priyanka; Nalawade, Apoorva Jagannath; Iyer, Deepak; Aich, Jyotirmoi

doi:10.1186/s43046-022-00137-0

Cited by 18 publications

(10 citation statements)

References 106 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unarguably, drug repurposing reduces the cost of research as well as speeds up manufacturing time. Still, somehow it deviates researchers and enforces to chase for some anti‐inflammatory, anti‐diabetic, antiviral, and anti‐fungal drugs instead of redesigning and reorganizing the currently used drugs to accomplish the essence of drug repurposing [181]. Although drug repurposing has become a convenient way to combat chemoresistance in modern research, this should not be the only reliable approach for BC therapeutics.…”

Section: Challenges Limitations and Suggestive Improvements For Onco‐...mentioning

confidence: 99%

Realm of proteomics in breast cancer management and drug repurposing to alleviate intricacies of treatment

Behera,

Bisht,

Giri

et al. 2023

Proteomics Clinical Apps

View full text Add to dashboard Cite

Breast cancer, a multi‐networking heterogeneous disease, has emerged as a serious impediment to progress in clinical oncology. Although technological advancements and emerging cancer research studies have mitigated breast cancer lethality, a precision cancer‐oriented solution has not been achieved. Thus, this review will persuade the acquiescence of proteomics‐based diagnostic and therapeutic options in breast cancer management. Recently, the evidence of breast cancer health surveillance through imaging proteomics, single‐cell proteomics, interactomics, and post‐translational modification (PTM) tracking, to construct proteome maps and proteotyping for stage‐specific and sample‐specific cancer subtyping have outperformed conventional ways of dealing with breast cancer by increasing diagnostic efficiency, prognostic value, and predictive response. Additionally, the paradigm shift in applied proteomics for designing a chemotherapy regimen to identify novel drug targets with minor adverse effects has been elaborated. Finally, the potential of proteomics in alleviating the occurrence of chemoresistance and enhancing reprofiled drugs' effectiveness to combat therapeutic obstacles has been discussed. Owing to the enormous potential of proteomics techniques, the clinical recognition of proteomics in breast cancer management can be achievable and therapeutic intricacies can be surmountable.

show abstract

Section: Challenges Limitations and Suggestive Improvements For Onco‐...mentioning

confidence: 99%

Realm of proteomics in breast cancer management and drug repurposing to alleviate intricacies of treatment

Behera,

Bisht,

Giri

et al. 2023

Proteomics Clinical Apps

View full text Add to dashboard Cite

show abstract

“…Mounting studies on anti-viral drugs have been focused on their anti-cancer properties ( 1 ). Acyclovir, as a synthetic nucleoside analog for attenuating the proliferation and spread of the herpes virus, has been reported to reveal benefit potentials when used as an adjuvant for the treatment of breast cancer ( 2 ).…”

Section: Introductionmentioning

confidence: 99%

Impact of oseltamivir on the risk of cancer

Chuang,

Tzang,

Tzang

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

PurposeMounting evidence has revealed the anti-cancer activity of various anti-viral drugs. Oseltamivir phosphate (OP), namely Tamiflu®, is routinely used to combat influenza infections. Although evidence has indicated the anti-cancer effects of OP in vitro and in vivo, little information is known about the effect of OP use on cancers in humans.MethodsA nationwide population-based cohort study involving 13,977,101 cases with 284,733 receiving OP was performed to examine the association between OP use and cancers using the National Health Insurance Research Database in Taiwan between 2009 and 2018.ResultsThe cohort study found that OP users showed a significantly lower incidence of lung cancer, colon cancer, liver, and intrahepatic bile duct cancer, oral cancer, pancreas cancer, esophagus cancer, stomach cancer, and prostate cancer. Additionally, OP users exhibited a lower risk of cancer-related mortality (adjusted HR=0.779; 95% confidence interval [CI] 0.743-0.817; p<0.001) and a reduced risk of developing liver cancer (adjusted HR=0.895; 95% CI 0.824-0.972; p=0.008), esophagus cancer (adjusted HR=0.646; 95% CI 0.522-0.799; p<0.001) and oral cancer (adjusted HR=0.587; 95% CI 0.346-0.995; p=0.048). Notably, OP users had a significant reduction in liver cancer occurrence over a 10-year period follow-up and a lower cancer stage at liver cancer diagnosis.ConclusionThese findings first suggest the beneficial effects and therapeutic potential of OP use for certain cancers, especially liver cancer.

show abstract

“…Several studies have indicated that central nervous system (CNS) drugs may be effective in suppressing the growth of cancer cell lines, e.g., colon, breast, and others [ 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 ]. Based on this knowledge, we hypothesized whether CNS drugs exhibit anticancer activity against SCC of the bladder when compared to antineoplastic drugs (depicted in Figure 1 ).…”

Section: Introductionmentioning

confidence: 99%

A Surprising Repurposing of Central Nervous System Drugs against Squamous Cell Carcinoma of the Bladder, UM-UC-5

Gouveia,

Ribeiro,

Vale

2024

Pharmaceutics

View full text Add to dashboard Cite

The potential benefits of drug repurposing have gained attention as an alternative to developing de novo drugs. The potential of using central nervous system (CNS) drugs as anticancer drugs has been explored in several types of human cancers, such as breast and colon cancer, among others. Here, we examine the effect of the CNS drugs sertraline, paroxetine, and chlorpromazine on human squamous carcinoma cells of the bladder (UM-UC-5). After exposing UM-UC-5 cells to increased concentrations of each drug for 48 h, we assessed their metabolic activity using an MTT assay. Based on those results, we calculated cell viability and the half-maximal inhibitory concentration (IC50) values. The results suggest that the CNS drugs were effective against UM-UC-5 in the order of potency of sertraline > chlorpromazine > paroxetine. Interestingly, sertraline was more potent than 5-fluorouracil (5-FU), a widely used anticancer drug. This study demonstrated, for the first time, the promising anticancer activity of CNS drugs on human bladder cancer cells in vitro and supports the repurposing of CNS drugs to improve cancer treatment. Nevertheless, further studies are necessary to understand their mechanism of action and in vivo activity.

show abstract

Drug repurposing: re-inventing therapies for cancer without re-entering the development pipeline—a review

Cited by 18 publications

References 106 publications

Realm of proteomics in breast cancer management and drug repurposing to alleviate intricacies of treatment

Realm of proteomics in breast cancer management and drug repurposing to alleviate intricacies of treatment

Impact of oseltamivir on the risk of cancer

A Surprising Repurposing of Central Nervous System Drugs against Squamous Cell Carcinoma of the Bladder, UM-UC-5

Contact Info

Product

Resources

About